A Study in Healthy Subjects to Evaluate Genetic Determinants of the Variability in Hemodynamic Response to Esmolol
Trial Snapshot
- Phase
- Not Applicable
- Enrollment
- 100
- Locations
- 1
- Primary Endpoint
- Change in heart rate during exercise
Study Overview
Brief Summary
Beta 1 Adrenergic antagonists (beta blockers) have major role in the treatment of CHF, IHD and hypertension. However, there is large interindividual variability in the response to beta blockers.
The hypothesis underlying this study is that genetic differences between individuals will determine the individual response to esmolol, a betablocker that is administered intravenously. Esmolol will be administered intravenously to healthy volunteers, and the effects on heart rate and blood pressure will be monitored. In addition, we will measure plasma renin activity and plasma levels of norepinephrine.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Basic Science
- Masking
- Single (Participant)
Eligibility Criteria
- Ages
- 18 Years to 50 Years (Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •healthy male and female
- •able to understand and sign informed consent
Exclusion Criteria
- •consumption of any medication
- •bradycardia <50 BPM
- •hypersensitivity to beta blockers
Arms & Interventions
esmolol infusion
infusion of esmolol during rest and exercise
Intervention: esmolol (Drug)
Outcomes
Primary Outcomes
Change in heart rate during exercise
Time Frame: 3 hours
continous measurement of heart rate
Secondary Outcomes
- change in systolic blood pressure during exercise(3 hours)